Research progress on prognosis and influencing factors of patients with radioactive iodine-refractory differentiated thyroid cancer

VernacularTitle:碘难治性分化型甲状腺癌患者预后及影响因素研究进展
Author: Liu XIN ¹ ; Zheng RONG
Author Information

1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院核医学科(北京市 100021)
Keywords: thyroid neoplasms; radioiodine; prognosis; therapy
From: Chinese Journal of Clinical Oncology 2024;51(6):318-322
CountryChina
Language:Chinese
Abstract: The incidence of thyroid cancer is steadily rising,with differentiated thyroid cancer(DTC)accounting for most cases.While stand-ard treatment offers a good prognosis for most DTC patients,a small subset experiences resistance to radioactive iodine during 131I therapy.This resistance is characterized by a lack of iodine uptake in lesions or continued disease progression,defined as radioactive iodine-refract-ory differentiated thyroid cancer(RAIR-DTC).Patients with RAIR-DTC face a significantly poorer prognosis and increased mortality.Several factors influence the prognosis of patients with RAIR-DTC,including age,tumor characteristics,genetic alterations,serum biomarkers,ima-ging findings,and different treatment modalities.This article provides a comprehensive overview of the outcomes and prognostic factors as-sociated with RAIR-DTC,aiming to provide assistance in timely evaluating the survival expectations of RAIR-DTC patients and guiding clinical decision-making.